Vihervuori E, Sipilä I, Siimes M A
Children's Hospital, University of Helsinki, Finland.
J Pediatr. 1994 Aug;125(2):242-5. doi: 10.1016/s0022-3476(94)70203-9.
We studied 36 children with short stature during the initial 6 months of recombinant human growth hormone treatment and found an elevation in the mean concentration of hemoglobin (p < 0.001). The elevation was highest in the eight patients with bone dysplasia (p < 0.001). The mean concentration of serum ferritin decreased (p < 0.01) and that of serum transferrin increased (p < 0.001). The prevalence of iron deficiency increased from 6 patients (17%) with initial deficiency to 20 (56%) patients after therapy, indicating that iron supplementation should be considered in children treated with recombinant human growth hormone.
我们研究了36名身材矮小儿童在重组人生长激素治疗的最初6个月期间的情况，发现血红蛋白平均浓度有所升高（p < 0.001）。在8名骨骼发育异常的患者中升高最为明显（p < 0.001）。血清铁蛋白平均浓度降低（p < 0.01），而血清转铁蛋白平均浓度升高（p < 0.001）。缺铁的患病率从最初有6名（17%）患者缺乏增加到治疗后20名（56%）患者，这表明接受重组人生长激素治疗的儿童应考虑补充铁剂。
